Post-market review of spinal cord stimulator devices
Published
Related content
-
Post-market review of facemasks closed
The COVID-19 pandemic post-market review of facemasks is now finished. -
TGA's decision to not register lecanemab (LEQEMBI)
TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease). -
Victorian fined for allegedly importing unapproved peptide
An individual based in Victoria has been fined $3,756 for the alleged unlawful importation of a peptide. They did not have approval to import the prescription-only medicine.